A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
After experiencing an ischaemic stroke or a mini-stroke (also called a transient ischaemic attack, or TIA), there is an increased risk of having another stroke. Doctors usually prescribe standard blood-thinning medicines, such as aspirin or clopidogrel, to help prevent blood clots from forming. This trial is testing an experimental medicine called milvexian. It works by blocking a specific clotting protein in the blood to stop harmful clots before they start. Researchers want to find out whether taking milvexian alongside standard treatment is better at preventing another stroke or heart attack than standard treatment alone. Participants will be randomly chosen to receive either milvexian tablets or dummy tablets (a placebo), taken in addition to standard care. Neither the participants nor their doctors will know which tablet they are receiving, ensuring the study results are fair and accurate.
At a glance
What is this study about?
An ischaemic stroke happens when a blood clot blocks blood flow to part of the brain, cutting off vital oxygen. A mini-stroke, or transient ischaemic attack (TIA), occurs when a clot causes temporary symptoms before clearing. Although symptoms from a mini-stroke may fade quickly, both conditions mean a person faces a higher risk of having another, potentially more severe stroke in the future.
Currently, doctors prescribe standard medications known as antiplatelets—such as aspirin and clopidogrel—to stop blood cells from sticking together. While these medicines are helpful, some people still go on to have another stroke. Milvexian is a new type of blood-thinning medicine designed to target a specific clotting factor in the blood. Scientists hope it can prevent dangerous clots in the brain and heart while lowering the chance of troublesome bleeding.
This Phase 3 study aims to confirm whether milvexian, when taken with standard medicines, reduces the chance of repeat strokes, heart attacks, and other serious blood clots. Finding new, more effective treatments could provide better long-term protection for stroke survivors in the UK and worldwide.
Key takeaways
- The trial tests a new blood thinner called milvexian to help prevent repeat strokes.
- It is open to adults aged 18 and older who recently had an ischaemic stroke or mini-stroke.
- Participants take either milvexian or a dummy pill alongside their standard medicines.
- Doctors will closely monitor participants for any signs of bleeding or side effects.
- Taking part is voluntary, and you can withdraw at any time without affecting your normal care.
Who may be eligible?
This trial is for adults aged 18 and over who have recently suffered an acute ischaemic stroke or a high-risk mini-stroke (TIA). Men and women are equally welcome to take part.
People who have had a stroke caused by bleeding in the brain (a haemorrhagic stroke) or who have an illness that causes active or severe bleeding will not be able to join. This is to protect patient safety.
The hospital research team will carry out detailed health checks, review your brain scans, and examine your current medicines to make sure taking part is completely safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have recently had an ischaemic stroke or a high-risk mini-stroke (TIA).
- My stroke was caused by a clot, not by bleeding in the brain.
- I do not have an active medical condition that causes serious bleeding.
- I am able and willing to attend regular hospital check-ups.
What does participation involve?
If you join the trial, you will be randomly assigned by a computer to take either milvexian or a matching dummy pill (placebo) once or twice a day by mouth. You will continue to take your regular stroke medicines as advised by your doctor.
The study usually lasts from several months up to a few years. During this time, you will have regular clinic visits for physical exams, blood pressure checks, and blood tests to monitor your health. The study team may also contact you by phone between visits to see how you are getting on. If you ever feel unwell or notice unusual symptoms, you can contact the research team at any time.
Potential risks and benefits
Locations (22)
- —UnverifiedBelgium
- —UnverifiedCzechia
- —UnverifiedPoland
- —UnverifiedFrance
- —UnverifiedFinland
- —UnverifiedPortugal
- —UnverifiedNetherlands
- —UnverifiedLithuania
- —UnverifiedDenmark
- —UnverifiedSlovakia
- —UnverifiedGreece
- —UnverifiedGermany
Common questions
What is a placebo?
A placebo is a dummy tablet that looks identical to the real medicine but contains no active ingredients. It helps researchers prove whether the new medicine truly works.
Will I still receive my normal stroke treatment?
Yes. All participants will continue to receive recommended standard stroke medicines, such as aspirin or clopidogrel, alongside the study tablet.
Will I know if I am taking milvexian or the placebo?
No. This is a 'double-blind' study, meaning neither you nor your doctor will know which tablet you receive until the trial is finished, unless there is a medical emergency.
Does taking part cost anything?
No. The trial medication, tests, and doctor visits are provided free of charge, and travel expenses to and from the hospital are often reimbursed.
Can I leave the study if I change my mind?
Yes. You can leave the study at any point without giving a reason, and your regular NHS medical care will continue as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.